In the Nov. 3, 2010 issue of the Journal of the American Medical Association (JAMA), researchers reported that the rate of cognitive and functional decline in patients with mild to moderate Alzheimer's disease was not slowed by supplementing with DHA, the most abundant long-chain omega 3 fatty acid in the brain.
The Global Organization for EPA and DHA Omega-3s (GOED), Salt Lake City, UT, has published a Rapid Review analyzing the JAMA study in its Advances in EPA and DHA Research journal. The complete review can be found here.
"While this trial examined DHA's impact on patients who already had Alzheimer’s disease, it's important to keep in mind that most experts emphasize omega 3's benefits likely lie in the prevention or delayed onset of many health conditions, including dementia and Alzheimer's,” said Harry Rice, PhD, vice president of regulatory and scientific affairs, GOED. “Two prior studies, MIDAS and OmegAD, were randomized, double-blind, placebo-controlled trials that showed a benefit to individuals with age-related cognitive decline or very mild Alzheimer's disease, respectively.
No comments:
Post a Comment